Yuki Nakagawa

No ORCID on file · 1 paper in corpus

nonrandomized-trial 2024

Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers

Journal for immunotherapy of cancer ·doi:10.1136/jitc-2024-009262

BACKGROUND: Immunosuppressive conditions within the tumor microenvironment (TME) can allow tumors to evade the immune system, including by hampering programmed death ligand 1 (PD-L1) inhibitor activity. Interleukin (IL)-8 contributes to imm…